Takeda ( TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily ...
The nonprofit Association of Migraine Disorders is reshaping public understanding of migraine through its global Shades For Migraine campaign. Designed to smash ...
The president organized the event on the White House's South Lawn as part of a dual birthday celebration for himself and the ...
For millions of people, cannabis has become the unofficial prescription for lost sleep. But what feels like a solution may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results